vimarsana.com

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.

“The IMpower130 trial defined a new standard of care for the treatment of extensive-stage small cell lung cancer, demonstrating a benefit for the addition of the PD-L1 inhibitor atezolizumab to a backbone of carboplatin and etoposide for the treatment of extensive-stage small cell lung cancer,” Charles M. Rudin, MD, chief of thoracic oncology at Memorial Sloan Kettering Cancer Center, said during his presentation at ASCO Annual Meeting. “Although this was a clinical advance, the vast majority of patients with extensive-stage small cell lung cancer continue to suffer disease progression with a median of about 5 and a half months from the time of diagnosis. So, there is clearly a major unmet need for the treatment of these patients.”

Related Keywords

Japan ,Chicago ,Illinois ,United States ,Charlesm Rudin ,Roche Genentech ,Genentech Roche ,Marleyv Ghizzone ,Amgen ,Astrazeneca ,Genentech ,Syros Pharmaceuticals ,Jazz Pharmaceuticals ,Memorial Sloan Kettering Cancer Center ,Bridge Medicines ,Harpoon Therapeutics ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.